There was a problem adding this course to your account. Please try again in a few minutes. If the problem persists, you can contact our support department at (877) 880-1335.
Adding Registration, Please wait...
You must be logged in to perform this action.
Log in
Cancel
Acute Repetitive Seizures: Emerging Treatments and Best Practices
Credit(s):
1.5 Contact Hour(s) of CE; 0.5 of which may be applied towards Pharmacology
Released: 03/10/2025 Expires: 03/31/2026 (subject to change)
CE for this activity will not be available after this date.
This activity includes closed captioning.
Overview
This activity explores the clinical challenges of acute repetitive seizures (ARS), also known as seizure clusters. The program addresses the burden of ARS, reviews clinical trial evidence and FDA-approved rescue therapies, and emphasizes the importance of patient and caregiver education. Participants will learn to develop customized treatment plans tailored to individual patient needs, with the goal of improving patient outcomes and quality of life. It also includes two case scenarios to enhance critical thinking, problem-solving, and decision-making skills.
Objectives
Determine the clinical burden of acute repetitive seizures (ARS) in patients with epilepsy.
Compare the clinical trial evidence and FDA-approved indications of the currently available rescue therapies for ARS.
Identify the key patient education teaching points for available ARS treatments.
Develop an individualized ARS treatment plan that achieves cluster cessation based on patient-specific, disease-specific, and rescue therapy-specific factors.
Speakers Lucretia Long, DNP Bethany Thomas, DNP Disclosure This program was planned in accordance with AANP CE Standards and Policies.
The speakers have the following disclosures:
Lucretia Long:
Advisory Board for Neurelis Incorporated, SK Life Science Inc., Catalyst Pharmaceutical, UCB Pharmaceutical
Speaker for Neurelis Incorporated, SK Life Science Inc.
I have not used artificial intelligence (AI) in the creation of this presentation.
Bethany Thomas:
Speaker bureau for LivaNova, Neurelis, Jazz Pharmaceuticals (Epilepsy)
Advisory Board for Jazz Pharmaceuticals and Xenon Pharmaceuticals
I have not used AI in the creation of this presentation.
All relevant financial relationships have been mitigated. All Planners involved in this activity have no relevant financial relationships to disclose.
Supported by an independent medical education grant from Neurelis, Inc. and UCB.
Disclaimer Individuals who have contributed to the CE Center were carefully selected for their knowledge and experience in the subject area under review. This presentation is informational only and may contain opinions of the authors from their personal experience that do not necessarily express the opinions of the American Association of Nurse Practitioners (AANP). The activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Clinical practice is a constantly changing process and new information becomes available every day. Neither AANP nor the contributing individuals can warrant that the material will continue to be accurate, nor do they warrant that the material is completely free of errors upon publication. Attendees and participants should appraise the information presented critically and are encouraged to consult appropriate resources for any product or device mentioned in this program. CE Credit Instructions
Read this activity description, including objectives and disclosures.
Complete the educational content:
Video Presentation:
Complete the Pretest associated to the activity.
Click the Play button to watch the activity presentation. Full participation credit for the activity will be received once the entire video has been watched.
Click on the Additional Resources button to review all additional materials provided (handouts, post-test reviews, any other downloadable resources).
After completing all content, click on the blue Next Steps button. Complete the post-test and then proceed to the c portion of the activity.
Case Scenarios:
Click the Play button on the Case Scenario activity block to launch the interactive activity. This activity will open in a new window. Complete all parts of the two interactive patient case scenarios.
Full participation credit for the activity will be received once the end of the activity has been reached and learner receives their activity participation code displayed on the screen. Learner must write down / remember the code in order to move on!
Click the Next Steps button and enter the participation code that was provided at the end of the case scenario activity. The code will consist of a LETTERS and NUMBERS. When entering the code in the Participation Code field, make sure you enter the letters and numbers together (no space between them). Letters are not case sensitive.
Activity Evaluation:
Click on the Next Steps button from the parent module (top activity block of the activity) and complete the activity evaluation to receive continuing education credit for the full activity.
Additional Information For questions or more information concerning this online CE activity,please visit the AANP Help Center to find answers to frequently asked questions and request assistance.
1.5 Contact Hour(s) of CE, 0.5 of which may be applied towards Pharmacology
Adding Registration, Please wait...
